Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BJTRF's Return-on-Tangible-Asset is ranked better than 74.4% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 3.12
vs BJTRF: 8.79
Beijing Tong Ren Tang Chinese Medicine Co (OTCPK:BJTRF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Beijing Tong Ren Tang Chinese Medicine Co Return-on-Tangible-Asset Related Terms
Beijing Tong Ren Tang Chinese Medicine Co Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beijing Tong Ren Tang Chinese Medicine Co Return-on-Tangible-Asset Chart
Beijing Tong Ren Tang Chinese Medicine Co Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beijing Tong Ren Tang Chinese Medicine Co Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of 7.19% mean?
Beijing Tong Ren Tang Chinese Medicine Co (BJTRF) has a Return-on-Tangible-Asset of 7.19% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Beijing Tong Ren Tang Chinese Medicine Co and its competitors. This is 58% below median its historical median of 16.95. Over the past decade, Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Asset has ranged from 8.74 to 20.09. According to the industry distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #258 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 25.6%.
Is Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Asset too high?
Beijing Tong Ren Tang Chinese Medicine Co's current Return-on-Tangible-Asset of 7.19% is 58% below median its 10-year median of 16.95. Over the past 10 years, this metric has ranged from a low of 8.74 to a high of 20.09. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.12. Beijing Tong Ren Tang Chinese Medicine Co's value of 7.19% is 130.4% above this industry median. Based on the distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #258 out of 1008 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Beijing Tong Ren Tang Chinese Medicine Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Beijing Tong Ren Tang Chinese Medicine Co's Return-on-Tangible-Asset compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beijing Tong Ren Tang Chinese Medicine Co ranks #258 out of 1008 companies for Return-on-Tangible-Asset. This puts Beijing Tong Ren Tang Chinese Medicine Co in the upper half of its industry. The industry median Return-on-Tangible-Asset is 3.12. Beijing Tong Ren Tang Chinese Medicine Co's value of 7.19% is 130.4% above this benchmark. Historically, Beijing Tong Ren Tang Chinese Medicine Co's own Return-on-Tangible-Asset has ranged from 8.74 to 20.09 over the past decade. While the company's 10-year median is 16.95 vs. the industry median of 3.12, Beijing Tong Ren Tang Chinese Medicine Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.12, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beijing Tong Ren Tang Chinese Medicine Co's current Return-on-Tangible-Asset of 7.19% is 130.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Beijing Tong Ren Tang Chinese Medicine Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beijing Tong Ren Tang Chinese Medicine Co's current Return-on-Tangible-Asset is 7.19%, which is 58% below median its own 10-year median of 16.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beijing Tong Ren Tang Chinese Medicine Co stock overvalued right now?
Beijing Tong Ren Tang Chinese Medicine Co (BJTRF) has a current Return-on-Tangible-Asset of 7.19%. The stock's GF Value™ is $0.94, compared to a current price of $0.65 — trading 31% below its estimated fair value. The current Return-on-Tangible-Asset is 7.19%, which is 58% below median its 10-year median of 16.95 and 130.4% above the Drug Manufacturers industry median of 3.12. Beijing Tong Ren Tang Chinese Medicine Co's overall GF Score™ is 89/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Beijing Tong Ren Tang Chinese Medicine Co (BJTRF), the current Return-on-Tangible-Asset is 7.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beijing Tong Ren Tang Chinese Medicine Co (BJTRF) Overvalued in 2026?
Based on GuruFocus' analysis, Beijing Tong Ren Tang Chinese Medicine Co stock appears to be undervalued.
The current stock price of $0.65 is trading 31% below its estimated GF Value™ of $0.94.
Key valuation signals for BJTRF:
Return-on-Tangible-Asset: 7.19% (58% below median its 10-year median of 16.95)
GF Value™: $0.94 vs. price of $0.65 (31% below fair value)
Industry Position: 130.4% above the Drug Manufacturers median (#258 of 1008)
No single metric tells the full story. See the BJTRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beijing Tong Ren Tang Chinese Medicine Co Business Description
Beijing Tong Ren Tang Chinese Medicine Co Ltd is a pharmaceutical retailer that specializes in Chinese medicine operating in three segments; Hong Kong includes the sale of Chinese medicine products and healthcare products and the provision of Chinese medical consultation and treatments through retail and wholesale of Chinese medicine products and healthcare products; Chinese Mainland (PRC, but excluding Hong Kong, Macao, and Taiwan) includes wholesale of healthcare products in Chinese Mainland and the sole distributor of Tong Ren Tang branded products of Tong Ren Tang Technologies and Tong Ren Tang Ltd; and Overseas includes retail and wholesale of Chinese medicine products and healthcare products and provision of Chinese medical consultation and treatments.
89GF Score
Get the complete analysis for BJTRF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJTRF has been successfully added to your 
